GLP-1 Insurance Coverage

Normalized pricing table

Every row is sorted by the recurring monthly figure used in the captured offer. Required memberships are added where known. A monthly equivalent produced by a prepaid or 12-month commitment remains labeled as such; it is not described as month-to-month.

How Peptides Editorial normalizes price

Microdose, standard dose and brand medication are different categories

Microdose is not a standardized FDA category. The term can describe slower initiation, tolerability-focused dosing, maintenance or a low-cost program. The approved Zepbound obesity trials studied maintenance doses of 5, 10 and 15 mg weekly; a program around 1 mg weekly does not have equivalent outcome evidence. Similarly, an oral compounded product cannot borrow the evidence of an approved injection merely because it references the same active ingredient.

Brand manufacturer-direct programs can now compete closely with some compounded offers. Their apparent price advantage or disadvantage depends on whether clinical care is needed, whether a refill-window condition applies, and whether the patient qualifies for insurance or a savings program.

Decision guide

• Editor’s pick for an all-in program: NexLife, when its 12-month plan fits ($139 tirzepatide, $119 semaglutide). It is not the lowest price we track.
• Month to month: Eden ($129 tirzepatide, $99 semaglutide, no membership) has the lowest standing rate in our table; Mochi prices by dose plus a $79 membership.
• FDA-approved medication without telehealth care: manufacturer-direct LillyDirect or NovoCare pathways.
• Insurance-first care: evaluate prior-authorization support, visit charges and the plan formulary rather than cash prices alone.
• Microdose: compare actual milligrams, clinical goal and commitment—not the word “microdose.”

Frequently asked questions

Sources and update rule

Primary manufacturer and provider pages document price and terms; FDA labels and peer-reviewed trials document clinical claims. Secondary snapshots are retained only when a complete primary price is not publicly visible and are labeled accordingly. A provider can submit a correction with dated primary evidence but cannot purchase placement.

How the market changed

Manufacturer-direct programs, oral GLP-1 approvals and lower self-pay prices have narrowed the historical gap between brand and compounded pathways. The correct comparison now includes clinical care, product approval status, route, refill conditions and insurance—not only the medication sticker price.

Foundayo, approved in April 2026, begins at $149 through LillyDirect for the applicable self-pay offer. Oral Wegovy also has a $149 entry point for specified doses. These oral products offer convenience but their trial results, administration and dose-response profiles differ from injections.

Annual-cost examples

Annual arithmetic is illustrative. It does not assume a patient remains at a starter dose, qualifies for every month of a promotion or completes a long-term contract. The checkout agreement controls.

Regulatory and continuity cost

A lower compounded price can carry non-price tradeoffs: the product lacks FDA premarket approval, the pharmacy or concentration can change, and broad shortage-based copying has ended. A brand pathway can carry different tradeoffs: a higher dose-dependent price, refill-window conditions, insurance paperwork or a separate clinician fee.

Continuity should be budgeted as well. Ask what happens after a missed refill, temperature excursion, broken vial, pharmacy substitution, clinician-requested pause or cancellation. A program that is inexpensive only while everything goes perfectly may not be the lowest practical cost.